Biomiga Diagnostics

Sorrento Therapeutics licenses Biomiga Diagnostics’ drug monitoring device

Wednesday, September 11, 2013

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, has secured an exclusive license for the worldwide rights to Biomiga Diagnostics‘ proprietary therapeutic drug monitoring (TDM) device for paclitaxel products. The agreement allows Sorrento to utilize the TDM device for the clinical development of individualized dosing regimens of Sorrento’s late-stage compound, Cynviloq (paclitaxel polymeric micelle).

[Read More]